Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

One-step preparation of a self-assembled bioconjugate nanovaccine against Brucella

19 Nov 2023

Abstract excerpt

Brucellosis, caused by Brucella, is a severe zoonosis, and the current Brucella live attenuated vaccine cannot be used in humans due to major safety risks. Although polysaccharide antigens can be used to prepare the Brucella vaccine, their lower immunogenicity limits them from producing efficient and broad protection. In this study, we produced a high-performance bioconjugate nanovaccine against different species...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Brucella: diagnosis, epidemiology, treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37981707
DOI: 10.1080/21505594.2023.2280377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

One-step preparation of a self-assembled bioconjugate nanovaccine against BrucellaPMID 37981707Read ↗

Eliciting B cell immunity against infectious diseases using nanovaccines.Semantic proximity Read ↗

Efficient Nanovaccine Delivery in Cancer ImmunotherapySemantic proximity Read ↗

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I StudySemantic proximity Read ↗

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read ↗

Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozymeSemantic proximity Read ↗

An mRNA vaccine encoding five conserved Group A Streptococcus antigensSemantic proximity Read ↗

An mRNA–Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-Resistant <i>Neisseria gonorrhoeae</i>Semantic proximity Read ↗

Precision-engineering of subunit vaccine particles for prevention of infectious diseasesSemantic proximity Read ↗

Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinologySemantic proximity Read ↗

Advances in nanobody multimerization and multispecificity: from in vivo assembly to in vitro productionSemantic proximity Read ↗

Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles.Semantic proximity Read ↗

In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.